Comparative Effectiveness of SGLT2 Inhibitors vs. Sitagliptin Add-on Therapy to Metformin inType-2 Diabetes

Authors

Chris Sevald, School of Population Health, Thomas Jefferson University

Document Type

Presentation

Publication Date

4-9-2015

Comments

Advisors:

Joseph Jackson and John McAna, Jefferson School of Population Health, Thomas Jefferson University

Abstract

SGLT2 inhibitors share practical features with the DPP-4 inhibitors. We use a systematic review and meta-analysis to compare benefits of approved SGLT2s and sitagliptin (a DPP-4 inhibitor) in the context of add-on therapy when first line metformin fails.

We use adjusted indirect comparisons (ICs) based on the pooled data from meta-analysis), to support inferences about which therapy is directionally better on glucose control, body weight, blood-pressure reduction and adverse events. Comparisons are based on data from 5 RCTs testing SGLT2-inhibitors as add-on to metformin, and 6 RCTS testing sitagliptin as add-on to metformin. We found parity in blood glucose control, and modest but meaningful differences in weight loss and blood-pressure control, in favor of the SGLT2s.

Presentation: 39 minutes

Recommended Citation

Sevald, Chris, "Comparative Effectiveness of SGLT2 Inhibitors vs. Sitagliptin Add-on Therapy to Metformin inType-2 Diabetes" (2015). Master of Science in Applied Health Economics and Outcomes Research Capstone Presentations. Presentation 5.
https://jdc.jefferson.edu/msaheor/5